September 27, 2016
Biodesix®’ VeriStrat® Test Identifies T790M-Mutated Advanced Non-Small Cell Lung Cancer Patients Who Are More Likely to Have Improved Progression-Free Survival on Third Generation EGFR-TKI Therapy
Blood-based proteomic test helps identify NSCLC patients for EGFR-TKI therapy
Combined results from subset analyses of the TIGER-X and TIGER-2 clinical trials show that the VeriStrat test stratifies T790M-mutated patients with previously-treated, ... Read more
September 23, 2016
Multi-Institutional Data Supporting Clinical Use of Biodesix’ Blood-Based Tests Presented Today at IASLC Conference
Shortening Time to Treatment; Providing Individualized and Optimal Treatment in Non-Small Cell Lung Cancer With Liquid Biopsies
Two independent studies verifying the clinical utility of the GeneStrat™ blood-based biopsy and the Biodesix Lung Reflex™ testing strategy for molecular testing of patients with non-small ... Read more
September 15, 2016
Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference: “Active Control of MALDI TOF Mass Spectra Acquisition With Internal Standards for Improved Quantitative Serum Protein Profiles”
Salzburg, Austria…Nicholas Dupuis, Ph.D, of Biodesix®, Inc. is speaking today at the MSACL 3rd Annual Conference, where he is the chairperson of the Protein Quantitation track. Dupuis is a ... Read more
August 23, 2016
WHAT: Dr. Heinrich Roder, Biodesix’ CTO and chair of the conference’s computational systems biology program, will speak on “Bridging the gap: From hypothesis-independent tests to understanding of biological mechanisms”, to introduce the Computational Systems biology track at the 6th International Conference on Bioinformatics & Systems Biology.
WHO: Heinrich Roder is an author of more than 100 publications ... Read more
July 5, 2016 Horizon Blue Cross Blue Shield (BCBS) of New Jersey has determined that the VeriStrat® proteomic test is now considered a medically necessary benefit for members with advanced NSCLC.
April 15, 2016
Three separate studies in patients with advanced stages of cancer investigate how blood tests can be used to select patients for therapy will be presented by Biodesix’ scientists and their collaborators at the AACR Annual Meeting in New Orleans.
One study, presented in collaboration with Dr. Jeffrey Weber at NYU Langone Medical Center, indicates the clinical ... Read more
April 4, 2016
VeriStrat®, Biodesix’ proteomic blood test for patients with advanced NSCLC, has received multiple positive coverage decisions in 2016. As a result, 200 million Americans now have insurance coverage for VeriStrat. The most recent positive coverage decisions include BlueCross BlueShield (BCBS) of Florida and Health Care Services Corporation (HCSC).
VeriStrat provides physicians with prognostic and predictive information ... Read more
March 9, 2016
Chief Technology Officer for Biodesix, Inc., Dr. Heinrich Roder, will present the company’s approach and recent results for a blood test stratifying patients for immunotherapy benefit on Thursday, March 10, at Molecular Med Tri-Conference.
By modifying ideas from the field of deep learning, Biodesix® can design clinically useful tests from multivariate data that have a high ... Read more